Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG-221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

    Summary
    EudraCT number
    2015-000344-42
    Trial protocol
    DE   GB   ES   DK   BE   AT   CZ   IT  
    Global end of trial date
    25 Mar 2024

    Results information
    Results version number
    v1(current)
    This version publication date
    09 Apr 2025
    First version publication date
    09 Apr 2025
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    AG-221-AML-004
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Bristol-Myers Squibb
    Sponsor organisation address
    Chaussée de la Hulpe 185, Brussels, Belgium, 1170
    Public contact
    Global Submission Management, Clinical Trials, Bristol-Myers Squibb International Corporation, mg-gsm-ct@bms.com
    Scientific contact
    Bristol-Myers Squibb Study Director, Bristol-Myers Squibb, mg-gsm-ct@bms.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    25 Mar 2024
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    25 Mar 2024
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
     The primary objective of the study was to determine the primary efficacy, measured as OS, of enasidenib compared with CCRs in subjects 60 years or older with AML refractory to or relapsed after second- or third-line AML therapy and positive for an IDH2 mutation.
    Protection of trial subjects
    The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization Good Clinical Practice Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    30 Dec 2015
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Australia: 9
    Country: Number of subjects enrolled
    Austria: 7
    Country: Number of subjects enrolled
    Belgium: 5
    Country: Number of subjects enrolled
    Brazil: 2
    Country: Number of subjects enrolled
    Canada: 15
    Country: Number of subjects enrolled
    China: 13
    Country: Number of subjects enrolled
    Czechia: 5
    Country: Number of subjects enrolled
    Denmark: 13
    Country: Number of subjects enrolled
    France: 54
    Country: Number of subjects enrolled
    Germany: 34
    Country: Number of subjects enrolled
    Italy: 20
    Country: Number of subjects enrolled
    Korea, Republic of: 6
    Country: Number of subjects enrolled
    Russian Federation: 15
    Country: Number of subjects enrolled
    Spain: 33
    Country: Number of subjects enrolled
    Taiwan: 5
    Country: Number of subjects enrolled
    Türkiye: 1
    Country: Number of subjects enrolled
    United Kingdom: 26
    Country: Number of subjects enrolled
    United States: 56
    Worldwide total number of subjects
    319
    EEA total number of subjects
    171
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    57
    From 65 to 84 years
    258
    85 years and over
    4

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    319 participants were randomized and 298 participants received treatment

    Period 1
    Period 1 title
    Randomized Period
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    AG-221
    Arm description
    Participants receive continuous 28-day cycles of AG-221 100 mg orally (PO) once a day (QD) for 28 days, plus best supportive care (BSC).
    Arm type
    Experimental

    Investigational medicinal product name
    AG-221
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    50mg, 100mg, 150mg, or 200mg

    Arm title
    Conventional Care Regimens (CCRs)
    Arm description
    Treatment options include BSC only, azacitidine SC + BSC, LDAC SC + BSC, or IDAC IV + BSC. BSC only: 28-day cycles including hydroxyurea (for leukocytosis/IDH syndrome), anti-infectives, analgesics, antiemetics, and nutritional support. AZA+BSC: Azacitidine 775 mg/m2/day SC for 7 days plus BSC in 28-day cycles. LDAC+BSC: Cytarabine 20 mg SC BID for 10 days plus BSC in 28-day cycles. IDAC+BSC: Cytarabine 0.5–1.5 g/m2/day IV for 3–6 days per institutional practice, followed by BSC. The content guides on treatments for hematologic disorders with varied dosing, combining supportive care to improve patient outcomes while considering institutional protocols.
    Arm type
    Experimental

    Investigational medicinal product name
    Low-Dose Cytarabine
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravascular use
    Dosage and administration details
    Subjects randomized to the LDAC treatment option will receive continuous 28-day cycles of cytarabine 20 mg SC BID for 10 days until the End of Trial. Subjects randomized to IDAC treatment option will receive 28-day cycles of cytarabine 0.5 to 1.5 g/m2/day IV for 3 to 6 days, per standard institutional practice, unless they are discontinued from the study treatment.

    Investigational medicinal product name
    Azacitidine
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder for suspension for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    100mg

    Number of subjects in period 1
    AG-221 Conventional Care Regimens (CCRs)
    Started
    158
    161
    Completed
    157
    141
    Not completed
    1
    20
         Adverse event, serious fatal
    1
    -
         Other reasons
    -
    20
    Period 2
    Period 2 title
    Treatment Period
    Is this the baseline period?
    No
    Allocation method
    Randomised - controlled
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    AG-221
    Arm description
    Participants receive continuous 28-day cycles of AG-221 100 mg orally (PO) once a day (QD) for 28 days, plus best supportive care (BSC).
    Arm type
    Experimental

    Investigational medicinal product name
    AG-221
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    50mg, 100mg, 150mg, or 200mg

    Arm title
    Conventional Care Regimens (CCRs)
    Arm description
    Treatment options include BSC only, azacitidine SC + BSC, LDAC SC + BSC, or IDAC IV + BSC. BSC only: 28-day cycles including hydroxyurea (for leukocytosis/IDH syndrome), anti-infectives, analgesics, antiemetics, and nutritional support. AZA+BSC: Azacitidine 775 mg/m2/day SC for 7 days plus BSC in 28-day cycles. LDAC+BSC: Cytarabine 20 mg SC BID for 10 days plus BSC in 28-day cycles. IDAC+BSC: Cytarabine 0.5–1.5 g/m2/day IV for 3–6 days per institutional practice, followed by BSC. The content guides on treatments for hematologic disorders with varied dosing, combining supportive care to improve patient outcomes while considering institutional protocols.
    Arm type
    Active comparator

    Investigational medicinal product name
    Low-Dose Cytarabine
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravascular use
    Dosage and administration details
    Subjects randomized to the LDAC treatment option will receive continuous 28-day cycles of cytarabine 20 mg SC BID for 10 days until the End of Trial. Subjects randomized to IDAC treatment option will receive 28-day cycles of cytarabine 0.5 to 1.5 g/m2/day IV for 3 to 6 days, per standard institutional practice, unless they are discontinued from the study treatment.

    Investigational medicinal product name
    Azacitidine
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder for suspension for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    100mg

    Number of subjects in period 2
    AG-221 Conventional Care Regimens (CCRs)
    Started
    157
    141
    Completed
    0
    0
    Not completed
    157
    141
         Adverse event, serious fatal
    38
    23
         Transition to commercially available treatment
    1
    1
         Consent withdrawn by subject
    10
    24
         Physician decision
    1
    -
         Disease Relapse
    28
    1
         Adverse event, non-fatal
    17
    12
         Progressive Disease
    53
    37
         Other reasons
    3
    39
         Hematopoietic Stem Cell Transplantation
    6
    2
         Lost to follow-up
    -
    1
         Protocol deviation
    -
    1

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    AG-221
    Reporting group description
    Participants receive continuous 28-day cycles of AG-221 100 mg orally (PO) once a day (QD) for 28 days, plus best supportive care (BSC).

    Reporting group title
    Conventional Care Regimens (CCRs)
    Reporting group description
    Treatment options include BSC only, azacitidine SC + BSC, LDAC SC + BSC, or IDAC IV + BSC. BSC only: 28-day cycles including hydroxyurea (for leukocytosis/IDH syndrome), anti-infectives, analgesics, antiemetics, and nutritional support. AZA+BSC: Azacitidine 775 mg/m2/day SC for 7 days plus BSC in 28-day cycles. LDAC+BSC: Cytarabine 20 mg SC BID for 10 days plus BSC in 28-day cycles. IDAC+BSC: Cytarabine 0.5–1.5 g/m2/day IV for 3–6 days per institutional practice, followed by BSC. The content guides on treatments for hematologic disorders with varied dosing, combining supportive care to improve patient outcomes while considering institutional protocols.

    Reporting group values
    AG-221 Conventional Care Regimens (CCRs) Total
    Number of subjects
    158 161 319
    Age Categorical
    Units: Participants
        ≥ 60 to < 70 years
    61 72 133
        ≥ 70 to < 80 years
    80 77 157
        ≥ 80 years
    17 12 29
    Age Continuous
    Units: Years
        arithmetic mean (standard deviation)
    71.4 ( 6.04 ) 70.5 ( 6.17 ) -
    Sex: Female, Male
    Units: Participants
        Female
    67 65 132
        Male
    91 96 187
    Race (NIH/OMB)
    Units: Subjects
        American Indian or Alaska Native
    0 0 0
        Asian
    12 12 24
        Native Hawaiian or Other Pacific Islander
    0 0 0
        Black or African American
    2 6 8
        White
    115 110 225
        More than one race
    0 0 0
        Unknown or Not Reported
    29 33 62
    Ethnicity (NIH/OMB)
    Units: Subjects
        Hispanic or Latino
    4 3 7
        Not Hispanic or Latino
    126 128 254
        Unknown or Not Reported
    28 30 58

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    AG-221
    Reporting group description
    Participants receive continuous 28-day cycles of AG-221 100 mg orally (PO) once a day (QD) for 28 days, plus best supportive care (BSC).

    Reporting group title
    Conventional Care Regimens (CCRs)
    Reporting group description
    Treatment options include BSC only, azacitidine SC + BSC, LDAC SC + BSC, or IDAC IV + BSC. BSC only: 28-day cycles including hydroxyurea (for leukocytosis/IDH syndrome), anti-infectives, analgesics, antiemetics, and nutritional support. AZA+BSC: Azacitidine 775 mg/m2/day SC for 7 days plus BSC in 28-day cycles. LDAC+BSC: Cytarabine 20 mg SC BID for 10 days plus BSC in 28-day cycles. IDAC+BSC: Cytarabine 0.5–1.5 g/m2/day IV for 3–6 days per institutional practice, followed by BSC. The content guides on treatments for hematologic disorders with varied dosing, combining supportive care to improve patient outcomes while considering institutional protocols.
    Reporting group title
    AG-221
    Reporting group description
    Participants receive continuous 28-day cycles of AG-221 100 mg orally (PO) once a day (QD) for 28 days, plus best supportive care (BSC).

    Reporting group title
    Conventional Care Regimens (CCRs)
    Reporting group description
    Treatment options include BSC only, azacitidine SC + BSC, LDAC SC + BSC, or IDAC IV + BSC. BSC only: 28-day cycles including hydroxyurea (for leukocytosis/IDH syndrome), anti-infectives, analgesics, antiemetics, and nutritional support. AZA+BSC: Azacitidine 775 mg/m2/day SC for 7 days plus BSC in 28-day cycles. LDAC+BSC: Cytarabine 20 mg SC BID for 10 days plus BSC in 28-day cycles. IDAC+BSC: Cytarabine 0.5–1.5 g/m2/day IV for 3–6 days per institutional practice, followed by BSC. The content guides on treatments for hematologic disorders with varied dosing, combining supportive care to improve patient outcomes while considering institutional protocols.

    Primary: Overall Survival (OS)

    Close Top of page
    End point title
    Overall Survival (OS)
    End point description
    The time between randomization and death from any cause. Participants who drop-out or are alive at the end of trial will have their OS times censored at the time of last contact, as appropriate.
    End point type
    Primary
    End point timeframe
    From randomization to death due to any cause (up to approximately 49 months)
    End point values
    AG-221 Conventional Care Regimens (CCRs)
    Number of subjects analysed
    158
    161
    Units: Months
        median (confidence interval 95%)
    6.5 (5.5 to 9.5)
    6.2 (4.6 to 7.7)
    Statistical analysis title
    Statistical Analysis for Primary OS
    Comparison groups
    Conventional Care Regimens (CCRs) v AG-221
    Number of subjects included in analysis
    319
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    = 0.2288
    Method
    Stratified Log Rank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.86
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.67
         upper limit
    1.1

    Secondary: Overall Response Rate

    Close Top of page
    End point title
    Overall Response Rate
    End point description
    Number of participants with MLFS + CR + CRi + CRp + PR according to modified International Working Group Acute Myeloid Leukemia (IWG AML) response criteria. Complete response (CR) and morphologic leukemia-free state (MLFS) are defined as <5% blasts in a BM aspirate sample with marrow spicules and a count of ≥200 nucleated cells. There should be no blasts with Auer rods and no extramedullary disease. CR must also include: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment. Complete remission with incomplete neutrophil recovery (CRi) is all criteria of CR except ANC. Complete remission with incomplete platelet recovery (CRp) is all criteria of CR except platelet count. Partial remission (PR) is defined as all hematologic criteria of CR with a >50% decrease in the percentage of BM blasts to 5% to 25%. (<5% considered if Auer rods are present).
    End point type
    Secondary
    End point timeframe
    From randomization up to approximately 99 months
    End point values
    AG-221 Conventional Care Regimens (CCRs)
    Number of subjects analysed
    158
    161
    Units: Count of Subjects
    64
    16
    Statistical analysis title
    Statistical Analysis for ORR
    Comparison groups
    AG-221 v Conventional Care Regimens (CCRs)
    Number of subjects included in analysis
    319
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    < 0.0001 [1]
    Method
    Cochran-Mantel-Haenszel
    Parameter type
    Odds ratio (OR)
    Point estimate
    6.08
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    3.32
         upper limit
    11.14
    Notes
    [1] - p-value from a Cochran-Mantel-Haenszel test comparing the response rates between the AG-221 group and the combined CCR group with stratification factors of prior intensive therapy for AML and primary refractory status

    Secondary: Event-Free Survival

    Close Top of page
    End point title
    Event-Free Survival
    End point description
    Time from randomization to documented morphologic relapse after complete remission/complete remission with incomplete neutrophil recovery/complete remission with incomplete platelet recovery (CR/CRi/CRp), progressive disease (PD) or death from any cause, whichever occurs first. Morphologic Relapse after CR/CRi/CRp is defined as either reappearance of ≥ 5% blasts in the BM not attributable to any other cause or the development of extramedullary disease. PD is defined as a > 50% increase of BM blast count percentage from baseline to ≥ 20% for participants with 5 to 70% BM blasts at baseline or a doubling of absolute blast count in peripheral blood from baseline to ≥ 10 x 109/L (10,000/μL) for participants with > 70% BM blasts at baseline or the development of new extramedullary disease.
    End point type
    Secondary
    End point timeframe
    From randomization to the date of documented morphologic relapse after CR/CRi/CRp, PD or death from any cause, whichever occurs first. (up to approximately 49 months)
    End point values
    AG-221 Conventional Care Regimens (CCRs)
    Number of subjects analysed
    158
    161
    Units: Months
        median (confidence interval 95%)
    4.9 (3.7 to 5.9)
    2.6 (1.9 to 4.4)
    Statistical analysis title
    Statistical Analysis for EFS
    Comparison groups
    AG-221 v Conventional Care Regimens (CCRs)
    Number of subjects included in analysis
    319
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    = 0.02
    Method
    Stratified Log Rank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.73
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.55
         upper limit
    0.95

    Secondary: Duration of Response

    Close Top of page
    End point title
    Duration of Response
    End point description
    Time from first documented response (MLFS/CR/CRi/CRp/PR) to morphologic relapse, progression, or death, whichever occurs first. CR/MLFS: <5% BM blasts in spicules with ≥200 nucleated cells, no Auer rod blasts, no extramedullary disease. CR also requires ANC ≥1,000/μL, platelets ≥100,000/μL, and no transfusions for ≥1 week. CRi excludes ANC; CRp excludes platelets. PR: All CR hematologic criteria with >50% BM blast decrease to 5-25%. Relapse (CR/CRi/CRp): BM blasts reappear ≥5% or extramedullary disease develops. PD: >50% BM blast increase to ≥20%, blood blasts double to ≥10,000/μL, or new extramedullary disease. Here "99999" means NA
    End point type
    Secondary
    End point timeframe
    From randomization to documented morphologic relapse after CR/CRi/CRp/ PD or death due to any cause, whichever occurs first (up to approximately 49 months)
    End point values
    AG-221 Conventional Care Regimens (CCRs)
    Number of subjects analysed
    64
    16
    Units: Months
        median (confidence interval 95%)
    7.4 (5.6 to 12.7)
    33.3 (2.5 to 99999)
    No statistical analyses for this end point

    Secondary: Time to Response

    Close Top of page
    End point title
    Time to Response
    End point description
    Time from randomization to first documented MLFS/CR/CRi/CRp/PR. Complete remission (CR) and morphologic leukemia-free state (MLFS) are defined as <5% blasts in a BM aspirate sample with marrow spicules and a count of ≥200 nucleated cells. There should be no blasts with Auer rods and no extramedullary disease. CR must also include the following conditions: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment. Complete remission with incomplete neutrophil recovery (CRi) is all criteria of CR except ANC. Complete remission with incomplete platelet recovery (CRp) is all criteria of CR except platelet count. partial remission (PR) is defined as all hematologic criteria of CR with a >50% decrease in the percentage of BM blasts to 5% to 25%. (<5% considered if Auer rods are present).
    End point type
    Secondary
    End point timeframe
    From randomization to to first documented MLFS/CR/CRi/CRp/PR (up to approximately 49 months)
    End point values
    AG-221 Conventional Care Regimens (CCRs)
    Number of subjects analysed
    25
    7
    Units: Days
        median (full range (min-max))
    58.0 (23 to 242)
    56.0 (27 to 63)
    No statistical analyses for this end point

    Secondary: Treatment Mortality at 60 Days

    Close Top of page
    End point title
    Treatment Mortality at 60 Days
    End point description
    The number of participant deaths from any cause within 60 days of initiation of study treatment.
    End point type
    Secondary
    End point timeframe
    From first dose to 60 days after first dose
    End point values
    AG-221 Conventional Care Regimens (CCRs)
    Number of subjects analysed
    158
    161
    Units: Participants
    27
    30
    No statistical analyses for this end point

    Secondary: Treatment Mortality at 30 Days

    Close Top of page
    End point title
    Treatment Mortality at 30 Days
    End point description
    The number of participant deaths from any cause within 30 days of initiation of study treatment.
    End point type
    Secondary
    End point timeframe
    From first dose to 30 days after first dose
    End point values
    AG-221 Conventional Care Regimens (CCRs)
    Number of subjects analysed
    158
    161
    Units: Participants
    10
    13
    No statistical analyses for this end point

    Secondary: One-Year Survival Rate

    Close Top of page
    End point title
    One-Year Survival Rate
    End point description
    The proportion of participants alive at 1 year after randomization
    End point type
    Secondary
    End point timeframe
    From randomization to 1 year after randomization
    End point values
    AG-221 Conventional Care Regimens (CCRs)
    Number of subjects analysed
    158
    161
    Units: Proportion of participants
        number (confidence interval 95%)
    0.379 (0.303 to 0.454)
    0.263 (0.193 to 0.337)
    No statistical analyses for this end point

    Secondary: Overall Remission Rate

    Close Top of page
    End point title
    Overall Remission Rate
    End point description
    The number of participants with CR + CRi + CRp according to modified International Working Group Acute Myeloid Leukemia (IWG AML) response criteria. Complete remission (CR) is defined as <5% blasts in a BM aspirate sample with marrow spicules and a count of ≥200 nucleated cells. There should be no blasts with Auer rods and no extramedullary disease. CR must also include the following conditions: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment. Complete remission with incomplete neutrophil recovery (CRi) is all criteria of CR except ANC. Complete remission with incomplete platelet recovery (CRp) is all criteria of CR except platelet count.
    End point type
    Secondary
    End point timeframe
    From randomization up to approximately 49 months
    End point values
    AG-221 Conventional Care Regimens (CCRs)
    Number of subjects analysed
    158
    161
    Units: Participants
    47
    10
    Statistical analysis title
    Statistical Analysis for Overall Remission Rate
    Comparison groups
    AG-221 v Conventional Care Regimens (CCRs)
    Number of subjects included in analysis
    319
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    < 0.0001
    Method
    Fisher exact
    Confidence interval

    Secondary: Complete Remission Rate

    Close Top of page
    End point title
    Complete Remission Rate
    End point description
    The number of participants with morphologic complete remission (CR) according to modified International Working Group Acute Myeloid Leukemia Response Criteria (IWG AML). CR is defined as less than 5% blasts in a BM aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. There should be no blasts with Auer rods and absence of extramedullary disease; plus the following conditions: absolute neutrophil count (ANC) ≥1,000/μL, Platelet count ≥100,000/μL, and independent of red cell transfusions for ≥1 week before each response assessment.
    End point type
    Secondary
    End point timeframe
    From randomization up to approximately 49 months
    End point values
    AG-221 Conventional Care Regimens (CCRs)
    Number of subjects analysed
    158
    161
    Units: Participants
    37
    6
    Statistical analysis title
    Statistical Analysis for CRR
    Comparison groups
    AG-221 v Conventional Care Regimens (CCRs)
    Number of subjects included in analysis
    319
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    < 0.0001
    Method
    Fisher exact
    Confidence interval

    Secondary: The Number of Participants that Underwent Hematopoietic Stem Cell Transplantation (HSCT)

    Close Top of page
    End point title
    The Number of Participants that Underwent Hematopoietic Stem Cell Transplantation (HSCT)
    End point description
    The number of participants that underwent hematopoietic stem cell transplantation during the study.
    End point type
    Secondary
    End point timeframe
    From randomization up to approximately 49 months
    End point values
    AG-221 Conventional Care Regimens (CCRs)
    Number of subjects analysed
    158
    161
    Units: Participants
    7
    2
    No statistical analyses for this end point

    Secondary: Hematologic Improvement Rate

    Close Top of page
    End point title
    Hematologic Improvement Rate
    End point description
    The number of participants with hematologic improvement neutrophil response (HI-N) + hematologic improvement platelet response (HI-P) + hematologic improvement erythroid response (HI-E) according to the International Working Group for Myelodysplastic Syndromes for Hematologic Improvement (IWG MDS HI) criteria. HI-E is defined as a hemoglobin increase by ≥ 1.5 g/dL and a relevant reduction in units of RBC transfusions by an absolute number of at least 4 RBC transfusions/8 week compared with the pretreatment transfusion number in the previous 8 week. HI-P is defined as an absolute increase of ≥ 30 X 10^9/L for participants starting with > 20 X and an increase from < 20 X 10^9/L to > 20 X 10^9/L and by at least 100%. HI-N is defined as At least 100% increase and an absolute increase > 0.5 X 10^9/L.
    End point type
    Secondary
    End point timeframe
    From randomization up to approximately 49 months
    End point values
    AG-221 Conventional Care Regimens (CCRs)
    Number of subjects analysed
    158
    161
    Units: Participants
    67
    18
    Statistical analysis title
    Statistical Analysis for HIR
    Comparison groups
    AG-221 v Conventional Care Regimens (CCRs)
    Number of subjects included in analysis
    319
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    < 0.0001
    Method
    Fisher exact
    Confidence interval

    Secondary: Time to Treatment Failure

    Close Top of page
    End point title
    Time to Treatment Failure
    End point description
    Time from randomization to discontinuation of study treatment due to any cause
    End point type
    Secondary
    End point timeframe
    From randomization to discontinuation of study treatment due to any cause (up to approximately 49 months)
    End point values
    AG-221 Conventional Care Regimens (CCRs)
    Number of subjects analysed
    158
    161
    Units: Months
        median (confidence interval 95%)
    4.9 (4.0 to 6.0)
    1.9 (1.4 to 2.5)
    Statistical analysis title
    Statistical Analysis for Time to Treatment Failure
    Comparison groups
    AG-221 v Conventional Care Regimens (CCRs)
    Number of subjects included in analysis
    319
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    < 0.0001
    Method
    Stratified Log Rank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.53
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.41
         upper limit
    0.67

    Secondary: The Number of Participants Experiencing Adverse Events (AEs)

    Close Top of page
    End point title
    The Number of Participants Experiencing Adverse Events (AEs)
    End point description
    The number of participants experiencing different types of adverse events (AE). An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A Serious Adverse Event (SAE) is any AE occurring at any dose that: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or constitutes an important medical event. All AEs were coded using the MedDRA Version 22.0. Adverse events were analyzed in terms of treatment-emergent AEs (TEAEs). A treatment-related TEAE was defined as a TEAE that was suspected by the investigator to be related to study treatment. The severity was graded by the study personnel based on NCI National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. TR= Treatment Related DI= Dose Interruption
    End point type
    Secondary
    End point timeframe
    Please fill in
    End point values
    AG-221 Conventional Care Regimens (CCRs)
    Number of subjects analysed
    157
    141
    Units: Participants
        Treatment-Emergent Adverse Event (TEAE)
    157
    131
        TEAE Related to Study Drug
    122
    86
        Grade ≥ 3 TEAE
    148
    112
        Grade ≥ 3 TEAE Related to Study Drug
    75
    49
        Serious TEAE
    139
    92
        Serious TEAE Related to Study Drug
    34
    30
        TEAE Leading to Discontinuation of Study Drug
    38
    16
        TR TEAE Leading to Discontinuation of Study Drug
    5
    6
        TEAE Leading to Study Drug Dose Reduction Only
    22
    3
        TR TEAE Leading to Study Drug Dose Reduction Only
    18
    3
        TEAE Leading to Study Drug Dose Interruption Only
    85
    36
        TR TEAE Leading to Study Drug DI Only
    46
    21
        TEAE Leading to Study Drug Dose Reduction or DI
    92
    37
        TR TEAE Leading to Study Drug Dose Reduction or DI
    56
    22
        TEAE Leading to Death
    79
    33
        Treatment-related TEAE Leading to Death
    1
    5
    No statistical analyses for this end point

    Secondary: The Percent of Participants Experiencing Clinically Significant Laboratory Abnormalities - Serum Chemistry

    Close Top of page
    End point title
    The Percent of Participants Experiencing Clinically Significant Laboratory Abnormalities - Serum Chemistry
    End point description
    The percent of participants with clinically significant serum chemistry laboratory abnormalities. A clinically significant laboratory abnormality is defined as meeting Grade 3 or Grade 4 criteria according to the Common Terminology Criteria for Adverse Events (CTCAE). Grade 3 is defined as severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care. Grade 4 is defined as life-threatening consequences; urgent intervention indicated. The chemistry panel includes sodium, potassium, calcium, magnesium, chloride, phosphorus, CO2, bicarbonate, blood urea nitrogen (BUN), creatinine, glucose, albumin, total protein, alkaline phosphatase (ALP), bilirubin (total and direct), uric acid, lactate dehydrogenase (LDH), AST/SGOT, ALT/SGPT, gamma glutamyl transpeptidase (GGT), amylase and lipase.
    End point type
    Secondary
    End point timeframe
    From first dose up to approximately 49 months
    End point values
    AG-221 Conventional Care Regimens (CCRs)
    Number of subjects analysed
    157
    141
    Units: Percent of Participants
        number (not applicable)
    42.7
    21.3
    No statistical analyses for this end point

    Secondary: The Percent of Participants Experiencing Clinically Significant Laboratory Abnormalities - Hematology

    Close Top of page
    End point title
    The Percent of Participants Experiencing Clinically Significant Laboratory Abnormalities - Hematology
    End point description
    The percent of participants with clinically significant hematology laboratory abnormalities. A clinically significant laboratory abnormality is defined as meeting Grade 3 or Grade 4 criteria according to the Common Terminology Criteria for Adverse Events (CTCAE). Grade 3 is defined as severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care. Grade 4 is defined as life-threatening consequences; urgent intervention indicated. The hematology panel includes complete blood count (CBC) with differential, including red blood cell (RBC) count, hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), white blood cell (WBC) count (with differential), absolute neutrophil count (ANC) and platelet count.
    End point type
    Secondary
    End point timeframe
    From first dose up to approximately 49 months
    End point values
    AG-221 Conventional Care Regimens (CCRs)
    Number of subjects analysed
    157
    141
    Units: Percent of Participants
        number (not applicable)
    94.3
    89.4
    No statistical analyses for this end point

    Secondary: The Percent of Participants Experiencing Clinically Significant Vital Sign Abnormalities

    Close Top of page
    End point title
    The Percent of Participants Experiencing Clinically Significant Vital Sign Abnormalities
    End point description
    The percent of participants with clinically significant vital sign abnormalities including weight, temperature, blood pressure, pulse rate, and respiratory rate.
    End point type
    Secondary
    End point timeframe
    From first dose up to approximately 49 months
    End point values
    AG-221 Conventional Care Regimens (CCRs)
    Number of subjects analysed
    157
    141
    Units: Percent of Participants
    0
    0
    No statistical analyses for this end point

    Secondary: Change from Baseline in the European Organization for Research and Treatment of Cancer Quality-of-Life questionnaire (EORTC QLQ-C30)

    Close Top of page
    End point title
    Change from Baseline in the European Organization for Research and Treatment of Cancer Quality-of-Life questionnaire (EORTC QLQ-C30)
    End point description
    The change from baseline in the EORTC QLQ-C30 questionnaire. The EORTC QLQ-C30 is composed of 30 items that address general physical symptoms, physical functioning, fatigue and malaise, and social and emotional functioning. Subscale scores are transformed to a 0 to 100 scale, with higher scores on functional scales indicating better function and higher scores on symptom scales indicating worse symptoms. A change of at least 10 points on the standardized domain scores was required for it to be considered meaningful. Results obtained just prior to the start of study treatment on Day 1 of Cycle 1 will serve as the baseline values. If not available, the most recent screening results prior to the start of study treatment on Day 1 of Cycle 1 will be considered the baseline values.
    End point type
    Secondary
    End point timeframe
    From baseline to cycle 2 day 1 (up to approximately 1 month)
    End point values
    AG-221 Conventional Care Regimens (CCRs)
    Number of subjects analysed
    106
    62
    Units: Change from baseline in QLQ-C30 score
    arithmetic mean (standard deviation)
        Global QoL
    -4.7 ( 20.18 )
    -4.0 ( 18.46 )
        Physical Functioning
    -3.1 ( 17.19 )
    -6.7 ( 21.32 )
        Role Functioning
    -3.8 ( 27.63 )
    -7.8 ( 29.98 )
        Cognitive Functioning
    -0.6 ( 16.89 )
    -5.1 ( 18.00 )
        Emotional Functioning
    0.9 ( 15.72 )
    -0.7 ( 18.44 )
        Social Functioning
    -0.6 ( 29.27 )
    -10.2 ( 31.56 )
        Fatigue
    5.5 ( 18.73 )
    7.5 ( 25.59 )
        Nausea / Vomiting
    9.0 ( 20.21 )
    1.9 ( 15.12 )
        Pain
    6.0 ( 23.37 )
    7.0 ( 30.11 )
        Dyspnea
    -1.3 ( 23.42 )
    0.0 ( 27.66 )
        Insomnia
    8.5 ( 26.85 )
    1.1 ( 33.04 )
        Appetite Loss
    10.7 ( 28.19 )
    8.6 ( 31.33 )
        Constipation
    2.8 ( 24.82 )
    1.6 ( 24.46 )
        Diarrhea
    4.1 ( 24.21 )
    1.6 ( 18.53 )
        Financial Difficulties
    -0.3 ( 24.12 )
    -3.2 ( 21.52 )
    No statistical analyses for this end point

    Secondary: The Percentage of Participants Experiencing Clinically Significant Electrocardiogram (ECG) Abnormalities

    Close Top of page
    End point title
    The Percentage of Participants Experiencing Clinically Significant Electrocardiogram (ECG) Abnormalities
    End point description
    The percent of participants with clinically significant ECG abnormalities. 12-lead ECG was assessed by a physician trained in ECG interpretation. Intervals including PR, QRS, QT and RR were collected, as well as heart rate and rhythm.
    End point type
    Secondary
    End point timeframe
    From first dose up to approximately 49 months
    End point values
    AG-221 Conventional Care Regimens (CCRs)
    Number of subjects analysed
    147
    120
    Units: Percentage of Participants
        number (not applicable)
    7.6
    2.1
    No statistical analyses for this end point

    Secondary: Change from Baseline in EQ-5D-5L Health Utility Index

    Close Top of page
    End point title
    Change from Baseline in EQ-5D-5L Health Utility Index
    End point description
    The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. These health states are converted to a single index value using the crosswalk method to the EQ-5D-3L value set from the United Kingdom (UK). The EQ-5D-3L health utility index based on the UK population weights range from -0.594 to 1.0 with higher scores indicating higher health utility. Baseline results are obtained just prior to the start of study treatment on Day 1 of Cycle 1 and will serve as the baseline values.
    End point type
    Secondary
    End point timeframe
    From baseline up to cycle 2 day 1 (up to approximately 1 month)
    End point values
    AG-221 Conventional Care Regimens (CCRs)
    Number of subjects analysed
    106
    62
    Units: Change from baseline in EQ-5D score
        arithmetic mean (standard deviation)
    -0.0738 ( 0.2128 )
    -0.0598 ( 0.2500 )
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Serious Adverse Events and Other (Not Including Serious) Adverse Events were collected form from first dose to 28 days after last dose (up to approximately 49 months).
    Adverse event reporting additional description
    Serious Adverse Events and Other (Not Including Serious) Adverse Events were assessed/monitored for the treated population. All-Cause Mortality was assessed for the randomized population.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    26.1
    Reporting groups
    Reporting group title
    AG-221
    Reporting group description
    Participants receive continuous 28-day cycles of AG-221 100 mg orally (PO) once a day (QD) for 28 days, plus best supportive care (BSC).

    Reporting group title
    BSC Only
    Reporting group description
    continuous 28-day cycles of BSC

    Reporting group title
    Azacitidine + BSC
    Reporting group description
    continuous 28-day cycles of azacitidine 75 mg/m2/day SC for 7 days, plus BSC

    Reporting group title
    LDAC + BSC
    Reporting group description
    continuous 28-day cycles of cytarabine 20 mg SC BID for 10 days, plus BSC

    Reporting group title
    IDAC + BSC
    Reporting group description
    28-day cycles of cytarabine 0.5 to 1.5 g/m2/day IV for 3 to 6 days, per standard institutional practice, plus BSC; only BSC given after IDAC therapy concludes per standard institutional practice.

    Serious adverse events
    AG-221 BSC Only Azacitidine + BSC LDAC + BSC IDAC + BSC
    Total subjects affected by serious adverse events
         subjects affected / exposed
    139 / 157 (88.54%)
    10 / 22 (45.45%)
    38 / 58 (65.52%)
    27 / 33 (81.82%)
    17 / 28 (60.71%)
         number of deaths (all causes)
    143
    20
    53
    32
    22
         number of deaths resulting from adverse events
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    ACUTE LEUKAEMIA
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    GASTRIC CANCER
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ONCOLOGIC COMPLICATION
         subjects affected / exposed
    2 / 157 (1.27%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 2
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    SQUAMOUS CELL CARCINOMA
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SQUAMOUS CELL CARCINOMA OF SKIN
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ACUTE LYMPHOCYTIC LEUKAEMIA
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ACUTE MYELOID LEUKAEMIA
         subjects affected / exposed
    6 / 157 (3.82%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    1 / 33 (3.03%)
    1 / 28 (3.57%)
         occurrences causally related to treatment / all
    0 / 6
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 5
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    ACUTE MYELOID LEUKAEMIA RECURRENT
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    DIFFERENTIATION SYNDROME
         subjects affected / exposed
    9 / 157 (5.73%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    9 / 9
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ENDOMETRIAL CANCER
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vascular disorders
    HAEMORRHAGE
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HYPOTENSION
         subjects affected / exposed
    6 / 157 (3.82%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    1 / 28 (3.57%)
         occurrences causally related to treatment / all
    0 / 6
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    ASTHENIA
         subjects affected / exposed
    2 / 157 (1.27%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    FATIGUE
         subjects affected / exposed
    4 / 157 (2.55%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 5
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    GENERAL PHYSICAL HEALTH DETERIORATION
         subjects affected / exposed
    14 / 157 (8.92%)
    1 / 22 (4.55%)
    0 / 58 (0.00%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 15
    0 / 1
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 8
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PYREXIA
         subjects affected / exposed
    15 / 157 (9.55%)
    0 / 22 (0.00%)
    2 / 58 (3.45%)
    3 / 33 (9.09%)
    5 / 28 (17.86%)
         occurrences causally related to treatment / all
    1 / 18
    0 / 0
    0 / 2
    0 / 3
    5 / 7
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    INFLUENZA LIKE ILLNESS
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    MALAISE
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    MUCOSAL INFLAMMATION
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    MULTIPLE ORGAN DYSFUNCTION SYNDROME
         subjects affected / exposed
    3 / 157 (1.91%)
    1 / 22 (4.55%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    1 / 28 (3.57%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 1
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 3
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    ORGAN FAILURE
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    PHYSICAL DECONDITIONING
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Immune system disorders
    GRAFT VERSUS HOST DISEASE
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Reproductive system and breast disorders
    BENIGN PROSTATIC HYPERPLASIA
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    ACUTE RESPIRATORY FAILURE
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CHRONIC OBSTRUCTIVE PULMONARY DISEASE
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    LUNG INFILTRATION
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    LUNG DISORDER
         subjects affected / exposed
    2 / 157 (1.27%)
    1 / 22 (4.55%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    EPISTAXIS
         subjects affected / exposed
    3 / 157 (1.91%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    1 / 3
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    DYSPNOEA
         subjects affected / exposed
    2 / 157 (1.27%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ORGANISING PNEUMONIA
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PLEURAL EFFUSION
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    2 / 58 (3.45%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    PNEUMONITIS
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    RESPIRATORY DISTRESS
         subjects affected / exposed
    3 / 157 (1.91%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    RESPIRATORY FAILURE
         subjects affected / exposed
    4 / 157 (2.55%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    1 / 5
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Psychiatric disorders
    CONFUSIONAL STATE
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Investigations
    BLAST CELL COUNT INCREASED
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    2 / 58 (3.45%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    ALANINE AMINOTRANSFERASE INCREASED
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    LIVER FUNCTION TEST INCREASED
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    BLOOD CREATININE INCREASED
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    EJECTION FRACTION DECREASED
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    GENERAL PHYSICAL CONDITION ABNORMAL
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    BLOOD BILIRUBIN INCREASED
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    TRANSAMINASES INCREASED
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PLATELET COUNT DECREASED
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    ANAPHYLACTIC TRANSFUSION REACTION
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    LOWER LIMB FRACTURE
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    INFUSION RELATED REACTION
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    FEMUR FRACTURE
         subjects affected / exposed
    2 / 157 (1.27%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    FALL
         subjects affected / exposed
    5 / 157 (3.18%)
    0 / 22 (0.00%)
    2 / 58 (3.45%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 5
    0 / 0
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ANKLE FRACTURE
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    2 / 28 (7.14%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    OVERDOSE
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SUBDURAL HAEMATOMA
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    POST PROCEDURAL HAEMORRHAGE
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    TRANSFUSION REACTION
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SUBDURAL HAEMORRHAGE
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac disorders
    ACUTE CORONARY SYNDROME
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ACUTE MYOCARDIAL INFARCTION
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    ANGINA PECTORIS
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ATRIAL FIBRILLATION
         subjects affected / exposed
    2 / 157 (1.27%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ATRIAL FLUTTER
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CARDIAC HYPERTROPHY
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CARDIAC ARREST
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CARDIAC FAILURE CONGESTIVE
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CARDIAC FAILURE
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    BRADYCARDIA
         subjects affected / exposed
    2 / 157 (1.27%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SINUS BRADYCARDIA
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PERICARDITIS
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PERICARDIAL EFFUSION
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CORONARY ARTERY DISEASE
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CARDIOMYOPATHY
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    ATAXIA
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    BRAIN OEDEMA
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CEREBRAL HAEMORRHAGE
         subjects affected / exposed
    4 / 157 (2.55%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    CEREBRAL INFARCTION
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ISCHAEMIC STROKE
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HAEMORRHAGE INTRACRANIAL
         subjects affected / exposed
    5 / 157 (3.18%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 5
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 5
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HEADACHE
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    INTRAVENTRICULAR HAEMORRHAGE
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    DYSARTHRIA
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SYNCOPE
         subjects affected / exposed
    4 / 157 (2.55%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    NORMAL PRESSURE HYDROCEPHALUS
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    LUMBOSACRAL RADICULOPATHY
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    LOSS OF CONSCIOUSNESS
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    FEBRILE NEUTROPENIA
         subjects affected / exposed
    33 / 157 (21.02%)
    5 / 22 (22.73%)
    14 / 58 (24.14%)
    13 / 33 (39.39%)
    7 / 28 (25.00%)
         occurrences causally related to treatment / all
    4 / 44
    0 / 5
    4 / 20
    3 / 15
    6 / 9
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    1 / 2
    0 / 0
    AGRANULOCYTOSIS
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ANAEMIA
         subjects affected / exposed
    7 / 157 (4.46%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    1 / 7
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    FEBRILE BONE MARROW APLASIA
         subjects affected / exposed
    3 / 157 (1.91%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 5
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    LEUKOSTASIS SYNDROME
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    NEUTROPENIA
         subjects affected / exposed
    3 / 157 (1.91%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    1 / 28 (3.57%)
         occurrences causally related to treatment / all
    1 / 3
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    LEUKOCYTOSIS
         subjects affected / exposed
    3 / 157 (1.91%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    LEUKAEMOID REACTION
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HYPERLEUKOCYTOSIS
         subjects affected / exposed
    2 / 157 (1.27%)
    1 / 22 (4.55%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    HAEMORRHAGIC DISORDER
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PANCYTOPENIA
         subjects affected / exposed
    4 / 157 (2.55%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    1 / 4
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    THROMBOCYTOPENIA
         subjects affected / exposed
    6 / 157 (3.82%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    3 / 7
    0 / 0
    0 / 1
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Eye disorders
    RETINAL HAEMORRHAGE
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    COLITIS
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ASCITES
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ABDOMINAL PAIN
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    DIARRHOEA HAEMORRHAGIC
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    DIARRHOEA
         subjects affected / exposed
    2 / 157 (1.27%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    1 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CROHN'S DISEASE
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CONSTIPATION
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ENTEROCOLITIS
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    1 / 28 (3.57%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ENTEROCOLITIS HAEMORRHAGIC
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    GASTROINTESTINAL DISORDER
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    GASTROINTESTINAL HAEMORRHAGE
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    MELAENA
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    LOWER GASTROINTESTINAL HAEMORRHAGE
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    INGUINAL HERNIA
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    GINGIVAL HYPERTROPHY
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    MOUTH HAEMORRHAGE
         subjects affected / exposed
    2 / 157 (1.27%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    OESOPHAGITIS
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    OESOPHAGEAL ULCER
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ODYNOPHAGIA
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    NAUSEA
         subjects affected / exposed
    3 / 157 (1.91%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ORAL BLOOD BLISTER
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    RECTAL HAEMORRHAGE
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    1 / 28 (3.57%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    STOMATITIS
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    VOMITING
         subjects affected / exposed
    2 / 157 (1.27%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    1 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    UPPER GASTROINTESTINAL HAEMORRHAGE
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatobiliary disorders
    CHOLANGITIS ACUTE
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CHOLELITHIASIS MIGRATION
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CHRONIC HEPATIC FAILURE
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HEPATOTOXICITY
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HEPATIC FAILURE
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HEPATIC CYTOLYSIS
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HYPERBILIRUBINAEMIA
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Skin and subcutaneous tissue disorders
    ECCHYMOSIS
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PURPURA
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    RASH
         subjects affected / exposed
    2 / 157 (1.27%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    TOXIC SKIN ERUPTION
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal and urinary disorders
    RENAL COLIC
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ACUTE KIDNEY INJURY
         subjects affected / exposed
    4 / 157 (2.55%)
    0 / 22 (0.00%)
    3 / 58 (5.17%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    1 / 4
    0 / 0
    1 / 3
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HAEMATURIA
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    OLIGURIA
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    1 / 28 (3.57%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    URINARY RETENTION
         subjects affected / exposed
    0 / 157 (0.00%)
    1 / 22 (4.55%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    RENAL IMPAIRMENT
         subjects affected / exposed
    2 / 157 (1.27%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    RENAL FAILURE
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    1 / 28 (3.57%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    Musculoskeletal and connective tissue disorders
    ARTHRALGIA
         subjects affected / exposed
    2 / 157 (1.27%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    BACK PAIN
         subjects affected / exposed
    2 / 157 (1.27%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    BONE PAIN
         subjects affected / exposed
    2 / 157 (1.27%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    JOINT EFFUSION
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    TENDONITIS
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    NECK PAIN
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    MUSCULAR WEAKNESS
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PAIN IN EXTREMITY
         subjects affected / exposed
    2 / 157 (1.27%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    ACUTE SINUSITIS
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ACARODERMATITIS
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ANAL ABSCESS
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CLOSTRIDIAL SEPSIS
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CELLULITIS
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CAMPYLOBACTER INFECTION
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    BRONCHOPULMONARY ASPERGILLOSIS
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    2 / 58 (3.45%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    BRONCHITIS
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    BREVIBACTERIUM INFECTION
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    1 / 28 (3.57%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    BACTERAEMIA
         subjects affected / exposed
    4 / 157 (2.55%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    APPENDICITIS
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CLOSTRIDIUM DIFFICILE COLITIS
         subjects affected / exposed
    4 / 157 (2.55%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    1 / 6
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    DEVICE RELATED INFECTION
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    COVID-19 PNEUMONIA
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CLOSTRIDIUM DIFFICILE INFECTION
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    DISSEMINATED MUCORMYCOSIS
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ESCHERICHIA SEPSIS
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ENTEROCOLITIS INFECTIOUS
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    EPIGLOTTITIS
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    1 / 28 (3.57%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ESCHERICHIA BACTERAEMIA
         subjects affected / exposed
    1 / 157 (0.64%)
    1 / 22 (4.55%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ENTEROCOCCAL INFECTION
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    GASTROENTERITIS
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    FURUNCLE
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ESCHERICHIA URINARY TRACT INFECTION
         subjects affected / exposed
    2 / 157 (1.27%)
    1 / 22 (4.55%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    GASTROINTESTINAL INFECTION
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HERPES SIMPLEX
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HEPATOSPLENIC CANDIDIASIS
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HEPATIC INFECTION
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    GINGIVITIS
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    INFECTION
         subjects affected / exposed
    4 / 157 (2.55%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    1 / 4
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    INFLUENZA
         subjects affected / exposed
    2 / 157 (1.27%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    INJECTION SITE CELLULITIS
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    INTERVERTEBRAL DISCITIS
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    MENINGITIS LISTERIA
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    LOCALISED INFECTION
         subjects affected / exposed
    0 / 157 (0.00%)
    1 / 22 (4.55%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    LIVER ABSCESS
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    KLEBSIELLA BACTERAEMIA
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    LOWER RESPIRATORY TRACT INFECTION
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    NEUTROPENIC SEPSIS
         subjects affected / exposed
    3 / 157 (1.91%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    1 / 4
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    NOCARDIA SEPSIS
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    NOCARDIOSIS
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    OTITIS EXTERNA
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PERIORBITAL CELLULITIS
         subjects affected / exposed
    2 / 157 (1.27%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    1 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PERIRECTAL ABSCESS
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PHARYNGITIS
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PNEUMONIA
         subjects affected / exposed
    27 / 157 (17.20%)
    2 / 22 (9.09%)
    8 / 58 (13.79%)
    4 / 33 (12.12%)
    3 / 28 (10.71%)
         occurrences causally related to treatment / all
    1 / 31
    0 / 2
    2 / 15
    1 / 4
    3 / 3
         deaths causally related to treatment / all
    0 / 6
    0 / 1
    0 / 2
    0 / 0
    1 / 1
    PNEUMONIA INFLUENZAL
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PNEUMONIA LEGIONELLA
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PNEUMONIA RESPIRATORY SYNCYTIAL VIRAL
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PNEUMONIA FUNGAL
         subjects affected / exposed
    5 / 157 (3.18%)
    0 / 22 (0.00%)
    2 / 58 (3.45%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 8
    0 / 0
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    PNEUMONIA BACTERIAL
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PSEUDOMONAS INFECTION
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PYELONEPHRITIS ACUTE
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    RESPIRATORY SYNCYTIAL VIRUS INFECTION
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SEPTIC SHOCK
         subjects affected / exposed
    6 / 157 (3.82%)
    2 / 22 (9.09%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    1 / 28 (3.57%)
         occurrences causally related to treatment / all
    0 / 6
    0 / 2
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 5
    0 / 2
    0 / 1
    0 / 0
    0 / 1
    SEPSIS
         subjects affected / exposed
    17 / 157 (10.83%)
    0 / 22 (0.00%)
    3 / 58 (5.17%)
    2 / 33 (6.06%)
    1 / 28 (3.57%)
         occurrences causally related to treatment / all
    0 / 21
    0 / 0
    0 / 3
    0 / 2
    1 / 1
         deaths causally related to treatment / all
    0 / 10
    0 / 0
    0 / 2
    0 / 0
    1 / 1
    RESPIRATORY TRACT INFECTION
         subjects affected / exposed
    2 / 157 (1.27%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SINUSITIS
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    STENOTROPHOMONAS INFECTION
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    STAPHYLOCOCCAL SEPSIS
         subjects affected / exposed
    2 / 157 (1.27%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    STAPHYLOCOCCAL BACTERAEMIA
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SKIN INFECTION
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    2 / 58 (3.45%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    2 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SUBCUTANEOUS ABSCESS
         subjects affected / exposed
    2 / 157 (1.27%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    TOOTH ABSCESS
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    UPPER RESPIRATORY TRACT INFECTION
         subjects affected / exposed
    2 / 157 (1.27%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    1 / 28 (3.57%)
         occurrences causally related to treatment / all
    1 / 2
    0 / 0
    0 / 0
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    VASCULAR DEVICE INFECTION
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    URINARY TRACT INFECTION ENTEROCOCCAL
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    URINARY TRACT INFECTION
         subjects affected / exposed
    4 / 157 (2.55%)
    1 / 22 (4.55%)
    0 / 58 (0.00%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 1
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    URETHRITIS
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    1 / 28 (3.57%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    DEHYDRATION
         subjects affected / exposed
    5 / 157 (3.18%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 5
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    DECREASED APPETITE
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    DIABETIC METABOLIC DECOMPENSATION
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    TUMOUR LYSIS SYNDROME
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HYPONATRAEMIA
         subjects affected / exposed
    3 / 157 (1.91%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    1 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HYPOKALAEMIA
         subjects affected / exposed
    4 / 157 (2.55%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HYPERGLYCAEMIA
         subjects affected / exposed
    2 / 157 (1.27%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    AG-221 BSC Only Azacitidine + BSC LDAC + BSC IDAC + BSC
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    154 / 157 (98.09%)
    11 / 22 (50.00%)
    52 / 58 (89.66%)
    30 / 33 (90.91%)
    24 / 28 (85.71%)
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    DIFFERENTIATION SYNDROME
         subjects affected / exposed
    16 / 157 (10.19%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences all number
    17
    0
    0
    0
    0
    Vascular disorders
    HYPOTENSION
         subjects affected / exposed
    15 / 157 (9.55%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    1 / 28 (3.57%)
         occurrences all number
    20
    0
    1
    0
    1
    HYPERTENSION
         subjects affected / exposed
    8 / 157 (5.10%)
    0 / 22 (0.00%)
    4 / 58 (6.90%)
    1 / 33 (3.03%)
    2 / 28 (7.14%)
         occurrences all number
    13
    0
    4
    1
    2
    HAEMATOMA
         subjects affected / exposed
    11 / 157 (7.01%)
    0 / 22 (0.00%)
    2 / 58 (3.45%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences all number
    12
    0
    2
    0
    0
    PHLEBITIS
         subjects affected / exposed
    2 / 157 (1.27%)
    1 / 22 (4.55%)
    3 / 58 (5.17%)
    0 / 33 (0.00%)
    1 / 28 (3.57%)
         occurrences all number
    2
    1
    3
    0
    1
    General disorders and administration site conditions
    INJECTION SITE PAIN
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    6 / 58 (10.34%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences all number
    0
    0
    9
    0
    0
    INFLUENZA LIKE ILLNESS
         subjects affected / exposed
    5 / 157 (3.18%)
    0 / 22 (0.00%)
    3 / 58 (5.17%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences all number
    5
    0
    4
    0
    0
    GENERAL PHYSICAL HEALTH DETERIORATION
         subjects affected / exposed
    10 / 157 (6.37%)
    1 / 22 (4.55%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    1 / 28 (3.57%)
         occurrences all number
    12
    1
    0
    0
    1
    FATIGUE
         subjects affected / exposed
    45 / 157 (28.66%)
    0 / 22 (0.00%)
    10 / 58 (17.24%)
    6 / 33 (18.18%)
    4 / 28 (14.29%)
         occurrences all number
    61
    0
    10
    6
    4
    ASTHENIA
         subjects affected / exposed
    29 / 157 (18.47%)
    2 / 22 (9.09%)
    13 / 58 (22.41%)
    5 / 33 (15.15%)
    4 / 28 (14.29%)
         occurrences all number
    32
    2
    17
    8
    4
    NON-CARDIAC CHEST PAIN
         subjects affected / exposed
    5 / 157 (3.18%)
    1 / 22 (4.55%)
    3 / 58 (5.17%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences all number
    7
    1
    3
    0
    0
    PYREXIA
         subjects affected / exposed
    37 / 157 (23.57%)
    4 / 22 (18.18%)
    14 / 58 (24.14%)
    5 / 33 (15.15%)
    5 / 28 (17.86%)
         occurrences all number
    51
    4
    17
    6
    6
    OEDEMA PERIPHERAL
         subjects affected / exposed
    33 / 157 (21.02%)
    1 / 22 (4.55%)
    13 / 58 (22.41%)
    6 / 33 (18.18%)
    2 / 28 (7.14%)
         occurrences all number
    43
    1
    18
    6
    4
    Reproductive system and breast disorders
    VAGINAL HAEMORRHAGE
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    2 / 28 (7.14%)
         occurrences all number
    1
    0
    1
    0
    2
    Respiratory, thoracic and mediastinal disorders
    PLEURAL EFFUSION
         subjects affected / exposed
    8 / 157 (5.10%)
    1 / 22 (4.55%)
    3 / 58 (5.17%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences all number
    8
    1
    3
    0
    0
    OROPHARYNGEAL PAIN
         subjects affected / exposed
    8 / 157 (5.10%)
    0 / 22 (0.00%)
    2 / 58 (3.45%)
    4 / 33 (12.12%)
    2 / 28 (7.14%)
         occurrences all number
    9
    0
    3
    5
    2
    EPISTAXIS
         subjects affected / exposed
    27 / 157 (17.20%)
    3 / 22 (13.64%)
    10 / 58 (17.24%)
    4 / 33 (12.12%)
    4 / 28 (14.29%)
         occurrences all number
    35
    3
    15
    4
    5
    DYSPNOEA
         subjects affected / exposed
    34 / 157 (21.66%)
    2 / 22 (9.09%)
    3 / 58 (5.17%)
    3 / 33 (9.09%)
    1 / 28 (3.57%)
         occurrences all number
    51
    2
    4
    5
    1
    COUGH
         subjects affected / exposed
    27 / 157 (17.20%)
    3 / 22 (13.64%)
    9 / 58 (15.52%)
    8 / 33 (24.24%)
    2 / 28 (7.14%)
         occurrences all number
    37
    3
    10
    10
    2
    Psychiatric disorders
    CONFUSIONAL STATE
         subjects affected / exposed
    9 / 157 (5.73%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    2 / 33 (6.06%)
    2 / 28 (7.14%)
         occurrences all number
    12
    0
    0
    2
    2
    ANXIETY
         subjects affected / exposed
    9 / 157 (5.73%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences all number
    9
    0
    0
    0
    0
    DEPRESSION
         subjects affected / exposed
    8 / 157 (5.10%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences all number
    8
    0
    1
    0
    0
    INSOMNIA
         subjects affected / exposed
    24 / 157 (15.29%)
    1 / 22 (4.55%)
    10 / 58 (17.24%)
    2 / 33 (6.06%)
    2 / 28 (7.14%)
         occurrences all number
    26
    1
    17
    2
    2
    Investigations
    ALANINE AMINOTRANSFERASE INCREASED
         subjects affected / exposed
    8 / 157 (5.10%)
    0 / 22 (0.00%)
    3 / 58 (5.17%)
    2 / 33 (6.06%)
    2 / 28 (7.14%)
         occurrences all number
    9
    0
    3
    2
    2
    ASPARTATE AMINOTRANSFERASE INCREASED
         subjects affected / exposed
    6 / 157 (3.82%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    1 / 33 (3.03%)
    2 / 28 (7.14%)
         occurrences all number
    6
    0
    1
    1
    2
    BLOOD ALKALINE PHOSPHATASE INCREASED
         subjects affected / exposed
    5 / 157 (3.18%)
    0 / 22 (0.00%)
    3 / 58 (5.17%)
    0 / 33 (0.00%)
    1 / 28 (3.57%)
         occurrences all number
    10
    0
    4
    0
    1
    BLOOD BILIRUBIN INCREASED
         subjects affected / exposed
    41 / 157 (26.11%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    1 / 33 (3.03%)
    2 / 28 (7.14%)
         occurrences all number
    67
    0
    1
    1
    2
    BLOOD CREATININE INCREASED
         subjects affected / exposed
    20 / 157 (12.74%)
    0 / 22 (0.00%)
    5 / 58 (8.62%)
    0 / 33 (0.00%)
    1 / 28 (3.57%)
         occurrences all number
    33
    0
    7
    0
    1
    C-REACTIVE PROTEIN INCREASED
         subjects affected / exposed
    8 / 157 (5.10%)
    0 / 22 (0.00%)
    4 / 58 (6.90%)
    3 / 33 (9.09%)
    1 / 28 (3.57%)
         occurrences all number
    9
    0
    4
    3
    3
    ELECTROCARDIOGRAM QT PROLONGED
         subjects affected / exposed
    8 / 157 (5.10%)
    0 / 22 (0.00%)
    3 / 58 (5.17%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences all number
    9
    0
    3
    0
    0
    WEIGHT DECREASED
         subjects affected / exposed
    14 / 157 (8.92%)
    0 / 22 (0.00%)
    4 / 58 (6.90%)
    1 / 33 (3.03%)
    2 / 28 (7.14%)
         occurrences all number
    16
    0
    5
    1
    2
    WEIGHT INCREASED
         subjects affected / exposed
    0 / 157 (0.00%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    1 / 33 (3.03%)
    3 / 28 (10.71%)
         occurrences all number
    0
    0
    0
    1
    3
    Injury, poisoning and procedural complications
    CONTUSION
         subjects affected / exposed
    12 / 157 (7.64%)
    0 / 22 (0.00%)
    3 / 58 (5.17%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences all number
    13
    0
    3
    1
    0
    FALL
         subjects affected / exposed
    13 / 157 (8.28%)
    0 / 22 (0.00%)
    4 / 58 (6.90%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences all number
    15
    0
    4
    1
    0
    Cardiac disorders
    TACHYCARDIA
         subjects affected / exposed
    2 / 157 (1.27%)
    2 / 22 (9.09%)
    1 / 58 (1.72%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences all number
    3
    2
    1
    1
    0
    Nervous system disorders
    HEADACHE
         subjects affected / exposed
    24 / 157 (15.29%)
    0 / 22 (0.00%)
    3 / 58 (5.17%)
    5 / 33 (15.15%)
    2 / 28 (7.14%)
         occurrences all number
    28
    0
    4
    6
    2
    DIZZINESS
         subjects affected / exposed
    23 / 157 (14.65%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences all number
    28
    0
    0
    1
    0
    DYSGEUSIA
         subjects affected / exposed
    12 / 157 (7.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    1 / 28 (3.57%)
         occurrences all number
    14
    0
    0
    0
    1
    PERIPHERAL SENSORY NEUROPATHY
         subjects affected / exposed
    4 / 157 (2.55%)
    0 / 22 (0.00%)
    3 / 58 (5.17%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences all number
    4
    0
    3
    1
    0
    Blood and lymphatic system disorders
    ANAEMIA
         subjects affected / exposed
    46 / 157 (29.30%)
    2 / 22 (9.09%)
    7 / 58 (12.07%)
    7 / 33 (21.21%)
    7 / 28 (25.00%)
         occurrences all number
    83
    2
    13
    13
    7
    FEBRILE NEUTROPENIA
         subjects affected / exposed
    14 / 157 (8.92%)
    0 / 22 (0.00%)
    7 / 58 (12.07%)
    2 / 33 (6.06%)
    4 / 28 (14.29%)
         occurrences all number
    17
    0
    12
    2
    5
    LEUKOCYTOSIS
         subjects affected / exposed
    20 / 157 (12.74%)
    2 / 22 (9.09%)
    3 / 58 (5.17%)
    3 / 33 (9.09%)
    2 / 28 (7.14%)
         occurrences all number
    29
    2
    3
    3
    4
    LEUKOPENIA
         subjects affected / exposed
    13 / 157 (8.28%)
    0 / 22 (0.00%)
    3 / 58 (5.17%)
    1 / 33 (3.03%)
    1 / 28 (3.57%)
         occurrences all number
    20
    0
    9
    6
    3
    THROMBOCYTOPENIA
         subjects affected / exposed
    48 / 157 (30.57%)
    2 / 22 (9.09%)
    17 / 58 (29.31%)
    5 / 33 (15.15%)
    7 / 28 (25.00%)
         occurrences all number
    71
    2
    26
    12
    14
    NEUTROPENIA
         subjects affected / exposed
    29 / 157 (18.47%)
    2 / 22 (9.09%)
    14 / 58 (24.14%)
    7 / 33 (21.21%)
    4 / 28 (14.29%)
         occurrences all number
    41
    2
    33
    10
    7
    Eye disorders
    DRY EYE
         subjects affected / exposed
    4 / 157 (2.55%)
    0 / 22 (0.00%)
    4 / 58 (6.90%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences all number
    4
    0
    4
    0
    0
    CONJUNCTIVAL HAEMORRHAGE
         subjects affected / exposed
    4 / 157 (2.55%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    2 / 33 (6.06%)
    0 / 28 (0.00%)
         occurrences all number
    4
    0
    2
    2
    0
    Gastrointestinal disorders
    ABDOMINAL DISTENSION
         subjects affected / exposed
    10 / 157 (6.37%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences all number
    13
    0
    0
    0
    0
    ABDOMINAL PAIN
         subjects affected / exposed
    17 / 157 (10.83%)
    0 / 22 (0.00%)
    5 / 58 (8.62%)
    2 / 33 (6.06%)
    1 / 28 (3.57%)
         occurrences all number
    21
    0
    6
    2
    1
    ABDOMINAL PAIN UPPER
         subjects affected / exposed
    11 / 157 (7.01%)
    2 / 22 (9.09%)
    4 / 58 (6.90%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences all number
    16
    2
    5
    0
    0
    CONSTIPATION
         subjects affected / exposed
    30 / 157 (19.11%)
    2 / 22 (9.09%)
    23 / 58 (39.66%)
    4 / 33 (12.12%)
    6 / 28 (21.43%)
         occurrences all number
    41
    2
    30
    4
    6
    DIARRHOEA
         subjects affected / exposed
    62 / 157 (39.49%)
    0 / 22 (0.00%)
    14 / 58 (24.14%)
    7 / 33 (21.21%)
    6 / 28 (21.43%)
         occurrences all number
    86
    0
    15
    7
    6
    DRY MOUTH
         subjects affected / exposed
    2 / 157 (1.27%)
    0 / 22 (0.00%)
    3 / 58 (5.17%)
    2 / 33 (6.06%)
    0 / 28 (0.00%)
         occurrences all number
    2
    0
    3
    2
    0
    NAUSEA
         subjects affected / exposed
    69 / 157 (43.95%)
    2 / 22 (9.09%)
    16 / 58 (27.59%)
    10 / 33 (30.30%)
    7 / 28 (25.00%)
         occurrences all number
    90
    2
    27
    18
    8
    MOUTH HAEMORRHAGE
         subjects affected / exposed
    10 / 157 (6.37%)
    1 / 22 (4.55%)
    3 / 58 (5.17%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences all number
    12
    1
    6
    1
    0
    MELAENA
         subjects affected / exposed
    1 / 157 (0.64%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    2 / 33 (6.06%)
    0 / 28 (0.00%)
         occurrences all number
    1
    0
    0
    2
    0
    HAEMORRHOIDS
         subjects affected / exposed
    5 / 157 (3.18%)
    1 / 22 (4.55%)
    5 / 58 (8.62%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences all number
    5
    1
    6
    1
    0
    GINGIVAL BLEEDING
         subjects affected / exposed
    11 / 157 (7.01%)
    1 / 22 (4.55%)
    2 / 58 (3.45%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences all number
    11
    1
    2
    1
    0
    DYSPEPSIA
         subjects affected / exposed
    9 / 157 (5.73%)
    1 / 22 (4.55%)
    1 / 58 (1.72%)
    1 / 33 (3.03%)
    1 / 28 (3.57%)
         occurrences all number
    10
    1
    1
    1
    1
    STOMATITIS
         subjects affected / exposed
    15 / 157 (9.55%)
    1 / 22 (4.55%)
    4 / 58 (6.90%)
    7 / 33 (21.21%)
    5 / 28 (17.86%)
         occurrences all number
    19
    1
    7
    7
    5
    VOMITING
         subjects affected / exposed
    40 / 157 (25.48%)
    1 / 22 (4.55%)
    9 / 58 (15.52%)
    5 / 33 (15.15%)
    1 / 28 (3.57%)
         occurrences all number
    56
    1
    15
    5
    2
    Hepatobiliary disorders
    HYPERBILIRUBINAEMIA
         subjects affected / exposed
    15 / 157 (9.55%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences all number
    18
    0
    1
    0
    0
    Skin and subcutaneous tissue disorders
    ERYTHEMA
         subjects affected / exposed
    6 / 157 (3.82%)
    0 / 22 (0.00%)
    5 / 58 (8.62%)
    1 / 33 (3.03%)
    1 / 28 (3.57%)
         occurrences all number
    6
    0
    5
    1
    1
    RASH MACULO-PAPULAR
         subjects affected / exposed
    9 / 157 (5.73%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    1 / 33 (3.03%)
    1 / 28 (3.57%)
         occurrences all number
    10
    0
    1
    2
    1
    RASH
         subjects affected / exposed
    11 / 157 (7.01%)
    0 / 22 (0.00%)
    6 / 58 (10.34%)
    0 / 33 (0.00%)
    1 / 28 (3.57%)
         occurrences all number
    13
    0
    7
    0
    1
    PRURITUS
         subjects affected / exposed
    13 / 157 (8.28%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences all number
    14
    0
    0
    1
    0
    PETECHIAE
         subjects affected / exposed
    13 / 157 (8.28%)
    0 / 22 (0.00%)
    4 / 58 (6.90%)
    4 / 33 (12.12%)
    0 / 28 (0.00%)
         occurrences all number
    14
    0
    4
    5
    0
    Renal and urinary disorders
    CHRONIC KIDNEY DISEASE
         subjects affected / exposed
    2 / 157 (1.27%)
    0 / 22 (0.00%)
    3 / 58 (5.17%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences all number
    2
    0
    3
    1
    0
    DYSURIA
         subjects affected / exposed
    2 / 157 (1.27%)
    0 / 22 (0.00%)
    3 / 58 (5.17%)
    0 / 33 (0.00%)
    1 / 28 (3.57%)
         occurrences all number
    2
    0
    3
    0
    1
    Musculoskeletal and connective tissue disorders
    ARTHRALGIA
         subjects affected / exposed
    13 / 157 (8.28%)
    1 / 22 (4.55%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    1 / 28 (3.57%)
         occurrences all number
    15
    1
    0
    0
    1
    BACK PAIN
         subjects affected / exposed
    21 / 157 (13.38%)
    0 / 22 (0.00%)
    3 / 58 (5.17%)
    2 / 33 (6.06%)
    1 / 28 (3.57%)
         occurrences all number
    23
    0
    3
    2
    1
    MUSCULAR WEAKNESS
         subjects affected / exposed
    11 / 157 (7.01%)
    1 / 22 (4.55%)
    0 / 58 (0.00%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences all number
    13
    1
    0
    0
    0
    PAIN IN EXTREMITY
         subjects affected / exposed
    20 / 157 (12.74%)
    0 / 22 (0.00%)
    6 / 58 (10.34%)
    5 / 33 (15.15%)
    1 / 28 (3.57%)
         occurrences all number
    26
    0
    6
    5
    1
    Infections and infestations
    URINARY TRACT INFECTION
         subjects affected / exposed
    12 / 157 (7.64%)
    2 / 22 (9.09%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences all number
    19
    2
    1
    0
    0
    BRONCHITIS
         subjects affected / exposed
    3 / 157 (1.91%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    2 / 33 (6.06%)
    1 / 28 (3.57%)
         occurrences all number
    3
    0
    0
    5
    1
    CELLULITIS
         subjects affected / exposed
    3 / 157 (1.91%)
    1 / 22 (4.55%)
    2 / 58 (3.45%)
    2 / 33 (6.06%)
    1 / 28 (3.57%)
         occurrences all number
    5
    1
    2
    2
    1
    INFECTION
         subjects affected / exposed
    2 / 157 (1.27%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    2 / 28 (7.14%)
         occurrences all number
    2
    0
    1
    0
    2
    ORAL CANDIDIASIS
         subjects affected / exposed
    10 / 157 (6.37%)
    1 / 22 (4.55%)
    2 / 58 (3.45%)
    1 / 33 (3.03%)
    0 / 28 (0.00%)
         occurrences all number
    13
    1
    2
    1
    0
    UPPER RESPIRATORY TRACT INFECTION
         subjects affected / exposed
    13 / 157 (8.28%)
    0 / 22 (0.00%)
    6 / 58 (10.34%)
    0 / 33 (0.00%)
    1 / 28 (3.57%)
         occurrences all number
    15
    0
    12
    0
    2
    TOOTH INFECTION
         subjects affected / exposed
    2 / 157 (1.27%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    2 / 33 (6.06%)
    0 / 28 (0.00%)
         occurrences all number
    2
    0
    0
    2
    0
    RHINITIS
         subjects affected / exposed
    4 / 157 (2.55%)
    0 / 22 (0.00%)
    3 / 58 (5.17%)
    0 / 33 (0.00%)
    1 / 28 (3.57%)
         occurrences all number
    4
    0
    3
    0
    1
    PNEUMONIA FUNGAL
         subjects affected / exposed
    3 / 157 (1.91%)
    0 / 22 (0.00%)
    3 / 58 (5.17%)
    0 / 33 (0.00%)
    0 / 28 (0.00%)
         occurrences all number
    3
    0
    3
    0
    0
    PNEUMONIA
         subjects affected / exposed
    13 / 157 (8.28%)
    1 / 22 (4.55%)
    7 / 58 (12.07%)
    0 / 33 (0.00%)
    2 / 28 (7.14%)
         occurrences all number
    17
    1
    9
    0
    3
    PHARYNGITIS
         subjects affected / exposed
    3 / 157 (1.91%)
    0 / 22 (0.00%)
    0 / 58 (0.00%)
    2 / 33 (6.06%)
    0 / 28 (0.00%)
         occurrences all number
    3
    0
    0
    2
    0
    Metabolism and nutrition disorders
    DECREASED APPETITE
         subjects affected / exposed
    49 / 157 (31.21%)
    1 / 22 (4.55%)
    13 / 58 (22.41%)
    5 / 33 (15.15%)
    2 / 28 (7.14%)
         occurrences all number
    62
    1
    15
    6
    2
    HYPERGLYCAEMIA
         subjects affected / exposed
    11 / 157 (7.01%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    1 / 33 (3.03%)
    2 / 28 (7.14%)
         occurrences all number
    18
    0
    6
    1
    2
    HYPERKALAEMIA
         subjects affected / exposed
    2 / 157 (1.27%)
    0 / 22 (0.00%)
    3 / 58 (5.17%)
    0 / 33 (0.00%)
    1 / 28 (3.57%)
         occurrences all number
    2
    0
    3
    0
    1
    HYPOCALCAEMIA
         subjects affected / exposed
    15 / 157 (9.55%)
    0 / 22 (0.00%)
    3 / 58 (5.17%)
    0 / 33 (0.00%)
    2 / 28 (7.14%)
         occurrences all number
    17
    0
    3
    0
    5
    HYPERURICAEMIA
         subjects affected / exposed
    17 / 157 (10.83%)
    0 / 22 (0.00%)
    1 / 58 (1.72%)
    0 / 33 (0.00%)
    1 / 28 (3.57%)
         occurrences all number
    24
    0
    1
    0
    1
    HYPOKALAEMIA
         subjects affected / exposed
    52 / 157 (33.12%)
    1 / 22 (4.55%)
    10 / 58 (17.24%)
    2 / 33 (6.06%)
    7 / 28 (25.00%)
         occurrences all number
    73
    1
    15
    6
    11
    HYPOMAGNESAEMIA
         subjects affected / exposed
    19 / 157 (12.10%)
    1 / 22 (4.55%)
    3 / 58 (5.17%)
    2 / 33 (6.06%)
    6 / 28 (21.43%)
         occurrences all number
    22
    1
    5
    4
    6
    HYPONATRAEMIA
         subjects affected / exposed
    10 / 157 (6.37%)
    0 / 22 (0.00%)
    2 / 58 (3.45%)
    1 / 33 (3.03%)
    1 / 28 (3.57%)
         occurrences all number
    11
    0
    10
    1
    3
    HYPOPHOSPHATAEMIA
         subjects affected / exposed
    9 / 157 (5.73%)
    0 / 22 (0.00%)
    3 / 58 (5.17%)
    0 / 33 (0.00%)
    1 / 28 (3.57%)
         occurrences all number
    10
    0
    5
    0
    1
    HYPOALBUMINAEMIA
         subjects affected / exposed
    13 / 157 (8.28%)
    2 / 22 (9.09%)
    4 / 58 (6.90%)
    0 / 33 (0.00%)
    2 / 28 (7.14%)
         occurrences all number
    14
    2
    10
    0
    3

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    30 Nov 2017
    Sample size was increased and statistical considerations were updated. Study duration was updated. AG-221 background information was updated according to the current version of AG-221 (enasidenib) Investigator’s Brochure (IB).  The terminal half-life of enasidenib in humans was updated to 137 hours.  Removal of evaluation of α-KG levels in plasma and bone marrow from exploratory endpoints Fasting (preferred) lipid panel was added at 2 more timepoints.  The fasting requirement for lipid panel was updated.  Frequency of assessing disease status in the follow-up phase was reduced.  Data collection of investigator-assessed response/ disease status to subsequent AML therapies was added.  Fasting requirement for taking AG-221 was removed.  Reference toxicities during AG-221 therapy were updated.  Restricted concomitant medications during AG-221 therapy were updated.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 21:49:50 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA